Ares Financial Consulting’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.88K Hold
49
– – ﹤0.01% 811
2026
Q2
$2.78K Buy
+49
New +$2.17K ﹤0.01% 834

Other funds holding TVTX

Ares Financial Consulting's TVTX Position: Q3 2026 in Review

Ares Financial Consulting held its Travere Therapeutics (TVTX) position steady in Q3 2026 at 49 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #811.

Ares Financial Consulting first reported a position in TVTX in Q2 2026 and has held it in 2 quarters since. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Ares Financial Consulting held 49 shares of Travere Therapeutics worth $2.88K as of Q3 2026.
  • Ares Financial Consulting left its Travere Therapeutics share count unchanged in Q3 2026.
  • Travere Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #811 holding.
  • Ares Financial Consulting first reported a position in Travere Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.